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Drug-induced acute hemolytic anemia led 
to the discovery of G6PD deficiency. How- 
ever, most clinical data are from isolated 
case reports. In 2 clinical trials of antima- 
larial preparations containing dapsone 
(4,4'-diaminodiphenylsulfone;  2.5 mg/kg 
once daily for 3 days), 95 G6PD-deficient 
hemizygous boys, 24 G6PD-deficient 
homozygous girls, and 200 girls heterozy- 
gous for G6PD deficiency received this 
agent. In the first 2 groups, there was 
a maximum decrease in hemoglobin 
averaging  -2.64  g/dL  (range  -6.70  to 
+0.30 g/dL), which was significantly 
greater than for the comparator group 
receiving artemether-lumefantrine (ad- 
justed difference -1.46 g/dL; 95% confi- 
dence interval -1.76, -1.15). Hemoglobin 
concentrations were decreased by > 40% 
versus pretreatment in 24/119 (20.2%) of 
the G6PD-deficient children; 13/119 (10.9%) 
required blood transfusion. In the 
heterozygous girls, the mean maximum 
decrease in hemoglobin was -1.83 g/dL 
(range +0.90 to -5.20 g/dL); 1 in 200 (0.5%) 
required blood transfusion. All children even- 
tually recovered. All the G6PD-deficient chil- 
dren had the G6PD A- variant, ie, mutations 
V68M and N126D. Drug-induced acute hemo- 
lytic anemia in G6PD A- subjects can be 
life-threatening, depending on the nature 
and dosage of the drug trigger. Therefore, 
contrary to current perception, in clinical 
terms the A- type of G6PD deficiency can- 
not be regarded as mild. This study is regis- 
tered at http://www.clinicaltrials.gov as 
NCT00344006  and  NCT00371735.  (Blood. 
2012;120(20):4123-4133) 
 
Introduction      
 
Glucose 6-phosphate dehydrogenase (G6PD) deficiency is com- 
mon in populations that have been exposed to malaria, either in the 
present or in the past.1-4 This association appears to have arisen 
through natural selection,5  as G6PD-deficient individuals are 
relatively protected from severe malaria.6-8 This is particularly 
important in children because most fatalities from malaria (� 85%) 
occur in patients younger than 5 years of age. Malaria has been a 
powerful selective force in endemic areas for several thousands 
of  years.  Thus,  it  is  perhaps  not  surprising  that  an  estimated 
330 million people worldwide are G6PD deficient.4 
G6PD catalyzes the first step in the pentose phosphate pathway, 
oxidizing glucose 6-phosphate to 6-phosphogluconolactone, coupled 
to the reduction of nicotinamide adenine dinucleotide phosphate 
(NADP) to NADPH. In the erythrocyte, a cell with limited 
metabolic resources, this is the rate-limiting step in the production 
of NADPH, a key redox metabolite. In steady-state conditions, 
NADPH produced in G6PD-deficient erythrocytes by residual 
G6PD activity is adequate. However, G6PD-deficient erythrocytes 
are uniquely sensitive to any extra oxidative stress: this will cause 
cellular damage and premature destruction of erythrocytes through 
both intravascular and extravascular hemolysis.9 Clinically, this 
manifests as acute hemolytic anemia (AHA) with malaise, weak- 
ness, and abdominal or lumbar pain, which may be associated with 
passing dark urine (hemoglobinuria), followed by jaundice.9 
The  best  characterized  exogenous  triggers  of  hemolysis  in 
G6PD-deficient subjects are, apart from infection, fava beans and 
 
drugs.10 The clinical course of primaquine-induced hemolysis 
(which eventually led to the discovery of G6PD deficiency11) was 
charted in detail more than half a century ago in 6 adult 
volunteers.12 Since then, numerous drugs have been implicated as 
causes of G6PD-related hemolysis, most notably dapsone and other 
sulfones, methylthioninium chloride, niridazole, nitrofurantoin, 
pamaquin, quinolones, rasburicase, and sulfonamides,13 although 
most reports are of isolated cases.14 
By the year 2000, the spread of chloroquine-resistant Plasmo- 
dium falciparum had made the malaria situation even worse than 
before in many African countries.15 The development of a combina- 
tion of chlorproguanil-dapsone, initiated in the 1990s, was acceler- 
ated as a response to this situation.16 A randomized trial of 
chlorproguanil-dapsone against sulfadoxine-pyrimethamine led to 
the combination receiving a license in 2003 under the name 
Lapdap. A greater number of hematologic adverse events occurred 
in the dapsone-containing arm versus the comparator.17,18 How- 
ever, the relative risk to G6PD-deficient versus G6PD-normal 
patients remained not exactly defined because G6PD genotyping 
was performed in some patients, but not prospectively.17-19 The 
safety risks of dapsone were outlined at a World Health Organiza- 
tion (WHO) Technical Consultation; G6PD testing was recom- 
mended before treatment and a hemoglobin level of < 7.0 g/dL 
was set as a contraindication for its use in any patient.18 
The WHO technical consultation noted that data addressing 
specifically the risk of G6PD-related AHA in patients with malaria 
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receiving dapsone were not available.18 Anemia had only been 
occasionally documented with a combination of pyrimethamine 
and dapsone that was introduced in 1953 (Maloprim) and used 
mostly for prophylaxis.20 Extensive use of dapsone in leprosy was 
generally at low doses and under conditions in which drug adverse 
event reporting would not be expected to occur. On the other hand, 
data from a study in adult healthy male volunteers had indicated 
that dapsone did decrease hemoglobin concentrations to a greater 
degree in primaquine-sensitive (ie, G6PD-deficient) individuals 
(n = 5) than in G6PD-normal control subjects (n = 10).21 
In consideration of these issues, the protocol for 2 large phase 
3 trials of the triple combination chlorproguanil-dapsone- 
artesunate (CDA) required G6PD genotyping of all patients and 
frequent blood monitoring.22,23 These studies, conducted at mul- 
tiple sites in Africa, included 1806 malaria patients exposed to 
dapsone (2.5 mg/kg once daily for 3 days); the majority (95.0%) 
were children younger than 15 years of age.22,23 G6PD A- was the 
only mutation detected.24  The data obtained in these trials deter- 
mined categorically that the use of CDA created an unacceptable 
risk  of  hemolysis  in  G6PD-deficient patients  with  malaria.22,23 
CDA development was discontinued and Lapdap voluntarily 
withdrawn.19,22,23 
In these CDA phase 3 trials, the risk of AHA was evaluated with 
the use of a composite “hemoglobin safety” end point, defined 
prospectively as a hemoglobin decrease of > 4.0 g/dL or > 40% 
versus pretreatment, or hemoglobin < 5.0 g/dL, or blood transfu- 
sion.22,23 When this composite end point was used, there was a 
significant difference between G6PD-normal and G6PD-deficient 
patients but not between G6PD-normal patients and female patients 
heterozygous for G6PD deficiency. This picture was clearly not the 
whole one because some heterozygous female patients had severe 
hemolysis.22,23 
Here, we are reporting in full on the clinical course of acute 
hemolytic events in 119 children (< 15 years) treated with dapsone 
(either as chlorproguanil-dapsone or as CDA) in phase 3 trials who 
were hemizygous or homozygous for G6PD A-. This series is the 
largest ever reported of the hematologic impact of any drug on 
G6PD-deficient subjects. Most studies of drug-induced AHA are 
retrospective in the sense that investigations were initiated only 
after the patient had become ill. In contrast, this report is compiled 
from data collected prospectively in which a standard protocol was 
used. This allows us to examine the onset and time course and the 
full spectrum of hematologic effects of dapsone-induced AHA. The 
large dataset also allows statistical analyses that were not possible 
within  the  individual  studies.  The  analysis  of  the  200  G6PD 
heterozygous females who received dapsone is unique in terms of 
pharmacogenetics because these individuals cannot be reliably 
identified by routine G6PD deficiency testing, only by appropriate 
genotyping. Overall, our findings indicate that contrary to a 
widespread perception, in many subjects with the African type of 
G6PD  deficiency (G6PD  A-),  AHA  is  not  mild  and  can  be 
life-threatening. 
 
 
 
Methods 
 
Study design 
 
Data were obtained from 2 multicenter, randomized, double-blind, clinical 
trials of CDA in acute P falciparum malaria. Details of the conduct of the 
2 studies are included in 2 previous articles.22,23  To summarize, patients 
were randomized 2:1 CDA versus the comparator. In study 006,23  both 
treatment   arms   contained   dapsone,   administered   as   CDA  or   as 
chlorproguanil-dapsone to patients ages > 1 year enrolled from centers in 
Ouagadougou, Burkina Faso; Kumasi, Ghana; Doneguebougou and Banam- 
bani, Mali; and Ile-Ife, Jos and Lagos, Nigeria, between April 2006 and 
May 2007. In study 005,22 CDA was compared with artemether- 
lumefantrine (AL) in patients ages > 1 to < 14 years enrolled from centers 
in Bobo-Dioulasso, Burkina Faso; Kintampo, Ghana; Eldoret, Kilifi, and 
Pingilikani, Kenya; Ibadan, Enugu, Jos, and Calabar, Nigeria; and Baga- 
moyo and Kiwangwa, Tanzania, between June 2006 and August 2007. 
Investigators were blind to drug treatment and G6PD genotype and 
phenotype. 
 
Ethics statement 
 
Both clinical trials were conducted according to Good Clinical Practices, 
applicable regulatory requirements, and the Declaration of Helsinki. Ethical 
approval was obtained from the participating center’s ethics committee or 
institutional review board and the WHO Special Program for Research and 
Training in Tropical Diseases. Parents or guardians of all patients provided 
written or oral witnessed informed consent; when patients were 12 years or 
older, their own assent was required as well. 
 
Participants 
 
Eligible subjects were of either sex presenting with microscopically 
verified  acute  uncomplicated  P falciparum  malaria  (parasite  count 
2000-200 000  f-LL-1),  fever  within  the  previous  24 hours,  hemoglobin 
> 7.0 g/dL or hematocrit > 25%, and weight > 7.5 kg. Exclusion criteria 
are detailed in the previously published articles.22,23 
 
Procedures 
 
During screening, a full medical history was obtained and a clinical 
examination performed. Asexual parasite counts were determined via the 
use of WHO methods.22,23,25 Eligible patients received CDA 2/2.5/4 mg/kg 
or  chlorproguanil-dapsone  2/2.5 mg/kg  (both  GlaxoSmithKline),  both 
given once daily for 3 days (days 0, 1, 2), or 6-dose AL (Novartis Pharma 
AG), also given over the course of 3 days.22,23 Patients remained hospital- 
ized between days 0 and 3 in study 005. In study 006, treatment was 
ambulatory from days 0 to 3; patients were subsequently visited at home 
from days 4 to 6 for early detection of clinical abnormalities. Follow-up was 
until day 42 in study 005 and day 28 in study 006. Venous blood samples 
(2 mL) for hematology evaluations were taken at pretreatment (day 0); days 
1, 2, 3, 7, 14, and 28 in both studies; and at day 42 in study 005. Clinical 
chemistry assessments were made in study 005 at pretreatment (day 0); 
days 3, 7, and 42 plus days 14 and 28 if previous results were abnormal; and 
in study 006 at pretreatment, days 3, 7, and 28 plus day 14 if previous 
results were abnormal. 
 
G6PD genotyping 
 
G6PD genotyping was performed at the Kenya Medical Research Institute, 
Nairobi, Kenya, with quality control conducted at the Shoklo Malaria 
Research Unit, Mae Sot, Thailand. PCR amplification was used on a section 
of the G6PD gene, including G6PD B (wild type), G6PD A (A376G), and 
G6PD A- (G202A, A542T, G680T, and T968C). The analytical methods 
have been reported previously.24 
 
Outcomes and statistical methods 
 
The analysis included all enrolled patients ages < 15 years with the G6PD 
genotype available and hemoglobin data at pretreatment, day 3, and day 7. 
Data for patients who received dapsone within the CDA or chlorproguanil- 
dapsone combination were pooled (referred to henceforth as the dapsone 
group) and compared with results from the AL treatment arm. Patient 
pretreatment data were reported by the use of descriptive statistics. Changes 
from pretreatment for hemoglobin and hematocrit were defined as the 
difference between the pretreatment value and the lowest posttreatment 
value (maximum decrease or minimum increase), referred to as the 
“maximum decrease.” For other parameters, changes from pretreatment 
were defined as the difference between the pretreatment value and the 
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Table 1. Pretreatment clinical and laboratory data 
 
 
 
Parameter 
G6PD-normal 
males 
(n = 806) 
Hemizygous G6PD-
deficient males (n = 
122) 
G6PD-normal 
females 
(n = 636) 
Heterozygous 
females 
(n = 236) 
Homozygous G6PD-
deficient females (n = 
30) 
 
All subjects 
(n = 1830) 
Age, y 4.4 ± 3.1 4.3 ± 3.2 4.6 ± 3.2 4.2 ± 3.1 3.9 ± 3.1 4.4 ± 3.1 
Temperature, °C 37.88 ± 0.99 37.75 ± 0.94 37.90 ± 0.96 37.81 ± 0.96 38.05 ± 0.91 37.87 ± 0.97 
Parasitemia, f-LL-1 52 516 (216-323 361) 65 220 (1626-705 600) 56 722 (185-389 415) 53 429 (484-303 400) 48 452 (1026-211 546) 54 876 (185-705 600) 
Hemoglobin, g/dL 10.00 ± 1.57 9.94 ± 1.59 10.19 ± 1.56 9.94 ± 1.36 9.47 ± 1.64 10.05 ± 1.55 
Hematocrit, % 30.5 ± 4.3 30.2 ± 4.6 31.0 ± 4.4 30.2 ± 3.8 29.0 ± 4.1 30.6 ± 4.3 
Reticulocytes, % 1.4 ± 1.6 1.5 ± 1.4 1.5 ± 1.9 1.4 ± 1.2 1.7 ± 1.4 1.5 ± 1.7 
WBC X109/L 9.6 ± 4.0 9.8 ± 4.3 9.6 ± 4.0 9.7 ± 3.8 9.0 ± 4.3 9.6 ± 4.0 
Unconj bil, f-Lmol/L 10.1 ± 11.1 11.5 ± 13.1 10.8 ± 10.5 12.3 ± 19.1 11.3 ± 8.8 10.7 ± 12.4 
Platelets X 109/L 197.0 ± 109.3 195.6 ± 88.9 199.3 ± 119.8 189.4 ± 98.6 216.4 ± 134.1 197.0 ± 111.0 
ALT, IU/L 26.1 ± 20.7 33.8 ± 82.7 31.8 ± 42.1 29.0 ± 32.2 26.2 ± 18.1 29.0 ± 37.6 
AST, IU/L 44.7 ± 32.3 52.4 ± 80.5 47.6 ± 44.6 43.8 ± 33.3 44.0 ± 23.8 46.1 ± 41.8 
Dapsone group, n 631 95 514 200 24 1464 
AL group, n 175 27 122 36 6 366 
AL indicates artemether-lumefantrine; ALT, alanine aminotransferase; AST, aspartate aminotransferase; Unconj bil, unconjugated bilirubin; and WBC, white blood cell. 
All baseline and laboratory values are mean ± SD except for parasitemia which is mean (range). 
 
highest posttreatment value (maximum increase or minimum decrease), 
referred to as the “maximum increase.” 
All statistical analyses were performed posthoc. Differences between 
populations were compared with ANOVA, where adjustments were made 
for sex, center, age, weight, pretreatment hemoglobin, and G6PD status and 
in the case of the dapsone group also for study (005 or 006). 
 
 
Results 
 
Patients 
 
Of 1830 patients with acute uncomplicated malaria, 928 were male 
and 902 female (Table 1). Of the males, 13.1% (122/928) were 
G6PD deficient. Among females, 26.2% (236/902) were heterozy- 
gous for G6PD deficiency (henceforth referred to as heterozy- 
gotes), and 3.3% (30/902) were homozygous for G6PD deficiency 
(henceforth referred to as homozygotes). On the basis of the 
frequency of the A- gene in male patients, these figures demon- 
strated no significant deviation from the Hardy-Weinberg equilib- 
rium.  Dapsone  was  received  by  119  G6PD-deficient  children 
(95  were  hemizygotes  and  24  homozygotes)  as  well  as  by 
200 heterozygotes. 
At the time they entered the study, most subjects were moder- 
ately anemic, probably resulting, at least in part, from their acute 
malaria (Table 1). Other pretreatment parameters were within normal 
limits, except for an elevated serum bilirubin, which commonly is 
observed in patients with acute malaria.26 There were no relevant 
differences in the mean values or the distributions of pretreatment 
parameters according to G6PD genotype (Table 1). There were no 
important differences in the pretreatment parameters of the dap- 
sone group compared with the AL group (data not shown). 
 
Clinical course in comparator group 
 
Patients receiving AL had a small mean decrease in hemoglobin 
concentration of -0.65 g/dL on day 1 (see supplemental Figure 1, 
available on the Blood Web site; see the Supplemental Materials 
link at the top of the online article). From day 2 onward, 
hemoglobin levels stabilized and then increased in the majority of 
patients (Figure 1). Statistical analyses showed that there was no 
effect of G6PD status on hematologic parameters that might 
suggest AHA in the AL group (Table 2). In principle, we can think 
of 2 not mutually exclusive explanations for this transient decrease 
in  hemoglobin:  (1) continuing  hemolysis  from  malaria  before 
parasitemia was cleared; (2) hemodilution as a result of adequate 
hydration being restored during clinical support of the patient. In 
corroboration of (1), we know it takes up to 48 hours to clear 
parasitemia22; in support of (2), other analytes, such as unconju- 
gated bilirubin, also decreased from day 1 to day 2 (Figure 2D). 
None of the children required blood transfusion. Thus, we confirm 
that there is no evidence of AHA with AL and in this respect, the 
children who received AL can be regarded as a control group. 
With respect to platelets, there was an unexplained greater 
increase in platelet counts in heterozygotes than in G6PD-normal 
or G6PD-deficient patients (Table 2). On the other hand, on 
treatment of malaria, there was no statistically significant differ- 
ence in platelets between G6PD-deficient and G6PD-normal pa- 
tients (18.0 X 109/L; 95% confidence interval [95% CI] -35.1, 
71.1; Table 2). 
 
Clinical course in G6PD-deficient children receiving dapsone 
 
Almost all of the G6PD-deficient children who received dapsone 
showed evidence of hemolysis, with a marked decrease in hemoglo- 
bin (Figure 1, Figure 3). Whereas before treatment the erythrocyte 
morphology often was normal, except for the presence of P falci- 
parum (Figure 4A), morphologic changes in the erythrocytes 
consistent with oxidative damage could be seen clearly in these 
G6PD-deficient children from day 1 (approximately 24 hours after 
the first dapsone dose), at a time when malaria parasites were still 
visible (Figure 4B). By day 3, the morphologic evidence of 
oxidative damage was prominent (Figure 4C). 
In most G6PD-deficient children receiving dapsone, there was a 
gradual recovery of hemoglobin, which returned to the original 
level between days 28 and 42: this was heralded by a highly 
significant increase in reticulocytes, peaking at day 7 (Figure 2B). 
There was also a peak in WBC count at day 7 in hemizygous 
G6PD-deficient boys (although not for homozygous G6PD- 
deficient girls; Figure 2C). A substantial fraction of hemolysis in 
G6PD-deficient subjects exposed to an oxidative agent is extravas- 
cular27  and therefore reflected in hyperbilirubinemia (Figure 2D). 
Statistical analysis of all of these findings is presented in Table 2. 
Unfortunately, we do not have complete records of hemoglobin- 
uria, a reliable index of intravascular hemolysis. 
Given the large number (n = 119) of G6PD-deficient hemizy- 
gous boys and homozygous girls who received dapsone, we can chart 
rather precisely the course of the hemolytic attack (Table 3). The average 
lowest hemoglobin concentration across the observation period 
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Figure 1. Change in hemoglobin concentrations relative to values obtained at day 1 in children receiving a dapsone-containing combination or AL for the treatment 
of falciparum malaria. For changes from pretreatment (day 0) values, see supplemental Figure 1. 
 
was 7.20 g/dL. The mean maximum decrease in hemoglobin versus 
pretreatment values was -2.64 g/dL. Considering that the majority 
of children were anemic before treatment, it is important also to 
consider the decrease in hemoglobin as the percentage of the 
pretreatment level; on average -26.0%. The mean maximum 
decrease versus the day 1 value was -2.08 g/dL. All of these 
parameters were significantly different from the AL group; statisti- 
cal data are presented in Table 3. 
In 13 of 119 (10.9%) G6PD-deficient children treated with 
dapsone, the hemolytic attack was severe enough to require blood 
transfusion, which was administered on days 4-7 (supplemental 
Table 1 and illustrative clinical summaries). One heterozygous 
female and 2 G6PD-normal male patients also required a blood 
transfusion. 
In 2 of the 95 G6PD-deficient hemizygous boys who received 
dapsone,  there  was  no  decrease  in  hemoglobin.  One  was  a 
4-year-old boy who had received a recent blood transfusion for 
“malarial anemia” and had a pretreatment hemoglobin level of 
11.4 g/dL.  It  seems  probable  that  the  transfused  (presumably 
G6PD-normal) erythrocytes “masked” hemolysis of the boy’s 
endogenous erythrocytes. The other was a 3-year-old hemizygous 
boy who had a pretreatment hemoglobin level of 7.9 g/dL; in this 
case, we can only speculate that the child, perhaps in response to 
preexisting anemia, might have had a young erythrocyte population 
that would be less sensitive to oxidative hemolysis. 
In the girls heterozygous for G6PD deficiency treated with 
dapsone (n = 200), the mean maximum decrease in hemoglobin 
concentration was -1.83 ± 1.09 g/dL. The maximum decrease 
in hemoglobin for heterozygotes was intermediate between that 
of G6PD-normal and G6PD-deficient patients (Figure 5). Statis- 
tical analysis showed that the mean maximum decrease in 
hemoglobin for heterozygotes was significantly less then that 
observed  for  G6PD-deficient  patients  (adjusted  difference 
-0.91 g/dL; 95% CI -0.68,  -1.14)  but significantly greater 
than for G6PD-normal patients (adjusted difference -4.3 95% 
CI -2.7,  -5.8;  Table 2). However, in some of the heterozy- 
gotes, the hemolytic attack was as severe as in some of the 
homozygous females (Figure 6). 
Methemoglobinemia is known to occur with dapsone; indeed, 
we found that in the children who received dapsone, the mean 
highest posttreatment level was 5.2%, (n = 30) whereas in those 
that received AL it was 1.9% (n = 10). Within the dapsone group, 
the mean highest posttreatment methemoglobin level in G6PD- 
deficient children (n = 5) was 8.0% (range 3.2%-15.1%), com- 
pared with 4.5% (range 1.5%-15.3%) in G6PD-normal children 
(n = 21; see supplemental Table 2 for individual patient data and 
supplemental Figure 2B for data summary). 
 
 
Discussion 
 
Dapsone regularly causes hemolysis in G6PD-deficient children 
with malaria. Morphologic changes in the erythrocytes of these 
children  were  visible  as  early  as  24 hours  after  the  start  of 
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therapy, and the consequent hemolysis resulted in a hemoglobin 
nadir recorded at day 7, with eventual recovery in most children 
by day 28. 
Although from different parts of Africa, the 119 G6PD-deficient 
boys and girls included in this analysis constitute a rather homog- 
enous group because they all presented with acute P falciparum 
malaria and received the same dose of dapsone (2.5 mg/kg/d given 
for 3 days) within the CDA or the chlorproguanil-dapsone combina- 
tion. In addition, they all had the same G6PD variant, A-. The 
hemolysis was associated with hyperbilirubinemia, and it was 
regularly followed by a significant reticulocyte response (Figure 2). 
To the best of our knowledge, the time course of these hematologic 
changes has never been previously reported for such a large series 
of G6PD-deficient patients with drug-induced AHA. Leukocytosis— 
with a predominance of granulocytes—may occur in favism,28 and 
here we confirm that it also occurs in drug-induced AHA. Although 
urinalysis was not performed routinely, dark urine was noted, 
particularly in the children who required blood transfusion. 
Dapsone-induced hemolysis had previously been studied experi- 
mentally in G6PD-deficient healthy adult male volunteers.21 Dap- 
sone was given for 21 days to 5 G6PD-deficient subjects in doses 
ranging from 25 to 200 mg/d (0.4-2.5 mg/kg/d) and to 10 G6PD- 
normal controls at doses of 50-300 mg/d (0.7-4.1 mg/kg/d).21 The 
one G6PD-deficient subject who received a dose similar to that in 
this  series  (200 mg/d,  equivalent  to  about  2.5 mg/kg/d)  had  a 
decrease  in  hemoglobin  of  approximately  -3.6  g/dL  (it  was 
expressed in the original article in terms of hematocrit). The other 
drug causing AHA in G6PD-deficient subjects that has been studied 
experimentally is primaquine: in 6 primaquine-sensitive (subse- 
quently proven to be G6PD-deficient) adult volunteers, 30 mg/d for 
6 days (approximately 0.4 mg/kg/d) caused a decrease in hemoglo- 
bin of approximately -4.0 g/dL.12 This was evident on day 2 to day 
3 (often associated with passing dark urine), reached a nadir about 
day 8, followed by recovery to pretreatment hemoglobin levels by 
about day 28, without blood transfusion.12,29,30 The authors re- 
marked that in the only subject who took part in both studies, the 
hemolysis caused by dapsone 100 mg/d was somewhat less than 
that caused by primaquine 30 mg/d.21 
Several factors can influence the severity of a drug-induced 
hemolytic attack in a G6PD-deficient subject, including the pharma- 
cology of the drug, the dose, the G6PD mutation, the age, and 
coexisting disease conditions. If we take into account the differ- 
ences between the current report and the volunteer studies, 
particularly with respect to age, the findings are remarkably similar. 
This is possibly because the volunteer subjects were all African- 
American, and it became known subsequently that the most 
common G6PD mutation in African-Americans is G202A, A376G 
(V68M, N126D),31 the same mutation found in the children in this 
study.24  On the other hand, there were 2 differences. First, in the 
volunteer studies, drug sensitivity decreased with continued drug 
challenge because of a gradual increase in the proportion of young 
erythrocytes, which have greater G6PD activity than aging cells.30 
This did not take place in the current study because dapsone was 
given for only 3 days. The other, more important difference is that 
the serious hemolytic effect of dapsone was made more dangerous 
and  sometimes  life-threatening  in  these  children  because  they 
had malaria, and particularly malarial anemia; at study start 93 of 
119 (78.2%) of the hemizygous G6PD-deficient children were 
anemic, and 7 of 119 (5.9%) were severely anemic (according to 
WHO definitions).32 In addition, the same absolute decrease in 
hemoglobin in a child must be regarded as more “severe” than a 
similar  decrease in  an  adult  male  because  normal  hemoglobin 
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Figure 2. Hemolytic anemia in G6PD-deficient children with malaria receiving therapy with a dapsone-containing combination. The 4 panels report the following 
clinically important parameters: (A) hematocrit; (B) reticulocytes; (C) white blood cell count; and (D) unconjugated bilirubin. In each panel, the shaded area reflects data from 
the control group (children receiving AL), and the line plots represent mean values ± SE for children receiving a dapsone-containing combination for the 2 male and the 
3 female G6PD genotypes. Similar panels for other laboratory parameters are in supplemental Figures 1 and 2. 
 
 
levels are lower in children younger 12 years of age (11.5 g/dL) 
than in adult men (13.0 g/dL).32 
 
Variable severity of hemolysis 
 
Of 119 G6PD-deficient children, 26 (21.8%) had a decrease in 
hemoglobin of only 13% or less (the mean change in the AL 
group) versus pretreatment. At the other end of the scale, 24 of 
119 (20.2%) G6PD-deficient children had a hemoglobin decrease 
> 40% versus pretreatment. Such a great variation may appear at 
first surprising. We did not measure G6PD enzyme activity in this 
study, but it is possible that in some patients, previous anemia 
associated with either malnutrition or malaria or both could 
generate a young erythrocyte population relatively resistant to the 
oxidative effect of dapsone. The intensity, duration, and variable 
combination of such factors could account for variability in the 
hemolytic response to dapsone. In addition, we know very little 
about the interactions of G6PD with other genetic traits that may 
affect the vulnerability of erythrocytes with respect to oxidative 
challenge. 
 
Mechanism of action of dapsone 
 
The most extensive use of dapsone has been in the long-term 
therapy of leprosy. In several studies, a decrease in the mean 
hemoglobin level of the order of between -1.0 g/dL and -2.0 g/dL 
has been documented; and in different studies from 5% to 25% of 
patients, not all of them G6PD deficient, have developed overt 
hemolytic anemia.33-35 Apparently, the oxidative action of dapsone 
is so potent that it can cause damage even to G6PD-normal 
erythrocytes, but it stands to reason that the damage will be far 
more severe when the erythrocytes are G6PD deficient. In the 
current study, there was no evidence of dapsone-related hemolysis 
in G6PD-normal children, possibly because of the short duration of 
dapsone therapy used to treat malaria. 
Although  the  precise  mechanisms  whereby  dapsone  (4,4'- 
diaminodiphenylsulfone, or DDS) causes methemoglobinemia and 
hemolysis are not fully elucidated, several points about its metabo- 
lism have been established (see supplemental Figure 3). First, the 
active molecule, DDS, can be inactivated by acetylation to 
monoacetyl dapsone; and the steady-state balance between DDS 
and monoacetyl dapsone can be influenced by genetic polymor- 
phism of N-acetyltransferase-2. DDS is also converted to a 
hydroxylamine derivative (DDS-NHOH) by enzymes of the P450 
cytochrome family; DDS-NHOH is the main metabolite thought to 
be responsible for the hematologic toxicity of dapsone.36,37 This 
toxicity depends in part on a reaction between DDS-NHOH and 
hemoglobin that, in the presence of oxygen, produces methemoglo- 
bin and nitroso-dapsone.36 Reactive oxygen radicals (ROS) are 
known to be generated whenever hemoglobin is converted to 
methemoglobin, perhaps in greater amounts in the presence of 
BLOOD, 15 NOVEMBER 2012 · VOLUME 120, NUMBER 20 DAPSONE-INDUCED HEMOLYSIS IN G6PD DEFICIENCY 4129 
 
H
e
m
o
g
lo
b
in
 c
o
n
c
e
n
tr
a
ti
o
n
, 
g
/d
L
 
H
e
m
o
g
lo
b
in
 c
o
n
c
e
n
tr
a
ti
o
n
, 
g
/d
L
 
 
 
A 
15 
14 
13 
12 
11 
10 
9 
8 
7 
6 
5 
4 
0 5 10 15 20 25 30 35 40 45 
Study  day 
B 
15 
14 
13 
12 
11 
10 
9 
8 
7 
6 
5 
4 
0 5 10 15 20 25 30 35 40 45 
Study  day 
Figure 3. Variability in hemoglobin levels in individual patients. (A) G6PD- 
deficient  hemizygous  male  patients  (n = 95);  (B)  G6PD-deficient  homozygous 
female patients (n = 24). 
 
 
DDS-NHOH and nitroso-dapsone.36 ROS are normally detoxified 
by GSH, the supply of which ultimately depends on G6PD (see 
supplemental Figure 3). Consistent with this, in liver microsomes 
GSH and NADPH are protective against dapsone-induced cellular 
damage, precisely the molecules that are in limited supply in 
G6PD-deficient erythrocytes.37 Thus, we can visualize how methe- 
moglobinemia follows dapsone administration independent of 
G6PD status (as we have indeed observed), whereas the threat 
posed by ROS to erythrocytes is much greater if these are deficient 
in G6PD. 
Recent work has shown that DDS-NHOH can produce changes 
in erythrocyte membrane proteins,38  specifically affecting the 
phosphorylation of band 3. This can cause hemolysis even in 
G6PD-normal individuals.33-35 However, in G6PD-deficient eryth- 
rocytes, membrane remodeling appears to be increased.38 Presum- 
ably membrane damage combined with the pressure from ROS 
ultimately causes the demise of G6PD-deficient cells. Coming back 
to our patients, serial blood smears have enabled us to visualize 
dapsone in action: on one hand, the malaria parasites are being 
dramatically affected—as expected—in number and in shape 
(Figure 4A-B), and at the same time the erythrocytes are experienc- 
ing severe oxidative damage (Figure 4B-C). It is probably the first 
time that this has been documented. 
 
Hemolysis in G6PD heterozygotes 
 
Data on drug-induced AHA in females heterozygous for G6PD 
deficiency are limited to case reports. This series included 200 girls 
who were heterozygous for G6PD A-. From the individual trials, it 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Blood smears from a 3-year-old boy with acute malaria and G6PD 
deficiency treated with chlorproguanil-dapsone. (A) Pretreatment: black arrows 
point to erythrocytes parasitized by P falciparum (ring forms), the white arrow points 
to an erythrocyte containing 2 rings of P falciparum. (B) Approximately 24 hours after 
starting treatment (day 1): on the left abnormally shaped parasites are seen within 
spherocytes, on the right a parasite in a severely contracted erythrocyte. (C) On day 
3: numerous contracted erythrocytes, spherocytes, and hemighosts (often referred to 
as “bite cells”; arrows). Inset: another hemighost at a greater magnification; the part of 
the erythrocyte that appears to be missing is the negative image of a Heinz body.51 
Slides were prepared with Giemsa stain and Zeiss immersion oil. An Orthoplan light 
microscope was used (Leitz). Panel C (except the inset) was taken with an objective 
Plan-Apochromatic X63 oil, aperture number 1.4 (Zeiss). The inset to panel C and all 
other photos were taken with objective X100 oil, aperture number 1.3 (Leitz). Imaging 
was with a ProgRes C10plus (Jenoptik-Laser Optik Systeme) with acquisition 
software ProgRes Capture Basic (Jenoptik) running under Windows XP on a 
personal computer (assembled). 
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Table 3. Changes in clinically important hematologic and clinical chemistry parameters in G6PD-deficient malaria patients after receiving 
dapsone 
 
Laboratory parameter 
Dapsone G6PD deficient 
(n = 119)* 
Control group 
(n = 366) 
Adjusted difference 
(95% CI)† 
 
Hemoglobin 
Lowest value, g/dL                                                                                     7.20 ± 1.50                                              8.64 ± 1.41                                 -1.04 (-1.29, -0.79) 
Maximum decrease from pretreatment, g/dL                                          -2.64 ± 1.58                                           -1.37 ± 1.06                                 -1.46 (-1.76, -1.15) 
Maximum decrease from pretreatment, %                                              -26.0 ± 13.9                                           -13.2 ± 9.9                                   -13.9 (-16.8, -11.0) 
Maximum decrease from day 1 value, g/dL                                            -2.08 ± 0.46                                           -0.56 ± 1.47                                 -1.61 (-1.91, -1.30) 
Day 7 value, g/dL                                                                                       7.50 ± 1.57                                              9.76 ± 1.48                                 -1.80 (-2.08, -1.51) 
Reticulocytes, % 
 
Highest value 6.4 ± 6.6 2.3 ± 2.5 1.4 (0.5-2.3) 
Maximum increase from pretreatment 4.9 ± 6.3 1.2 ± 2.3 1.4 (0.5-2.3) 
White blood count, x109/L    
Highest value 13.9 ± 5.9 11.8 ± 4.5 2.3 (1.1-3.5) 
Maximum increase from pretreatment 4.0 ± 5.8 2.9 ± 4.1 1.7 (0.5-2.9) 
Unconjugated bilirubin, f.1mol/L    
Highest value 12.9 ± 14.3 4.1 ± 5.5 5.0 (2.3-7.8) 
Maximum increase from pretreatment 4.4 ± 13.7 -1.1 ± 7.3 4.4 (1.0-7.9) 
Values are mean ± SD except where indicated otherwise. The control group received artemether-lumefantrine. Changes from pretreatment were defined as maximum 
decrease (or minimum increase) for hemoglobin and hematocrit and as maximum increase (or minimum decrease) for other parameters. 
*Total of 95 G6PD-deficient hemizygous male plus 24 G6PD-deficient homozygous female patients. 
†Difference between treatment groups adjusted for sex, center, age, weight, pretreatment hemoglobin, and G6PD status. For dapsone subjects, a term was also fitted for 
study (trial 005 or 006). 
 
 
appeared that female heterozygotes were at no greater risk of 
clinically significant hemolysis than G6PD normal patients.22,23 
However, the greater power of the current pooled analysis has 
allowed us to outline the spectrum of severity of hemolysis in 
heterozygotes. As expected, overall this is significantly less than 
in G6PD-deficient children and is highly variable (Table 2, 
Figure 5) as can be expected from erythrocyte mosaicism. 
Indeed, as a result of random X-chromosome inactivation in 
G6PD heterozygotes, on average 50% of erythrocytes will be 
G6PD deficient, but the scatter around this mean is wide.39,40 
One would expect, therefore, that the severity of hemolysis in 
heterozygotes will be, on average, approximately half that 
observed for hemizygous G6PD-deficient males. This is indeed 
the case with respect to favism41; and it has been assumed, but 
had been never previously proven, for drug-induced AHA. Here 
for the first time it has become possible to test this theoretical 
prediction. We found that indeed the decrease in hemoglobin in 
this group was approximately half way between that of G6PD- 
normal and that of G6PD-deficient children (Figure 5). At the 
same time, not surprisingly, within the heterozygote group there 
were individual cases with severe hemolysis or hardly any 
hemolysis (Figure 6). 
Hemolysis and AL 
 
We found no evidence of G6PD-related hemolysis with AL. A 
mild decrease in hemoglobin from day 0 to day 1 was reversed 
in the first few days of therapy across all G6PD genotypes. The 
mechanism of action of artemisinins is thought to involve the 
alkylation of heme digested by P falciparum,42 although artemis- 
inin activation also can be triggered by undigested hemoglo- 
bin.43 There are a few cases in the literature of hemolytic anemia 
during or after treatment with intravenous artesunate alone or in 
combination with mefloquine, and one report after oral treat- 
ment with AL in a (G6PD normal) patient with HIV and severe 
falciparum malaria.44 However, these are rare adverse events. It 
appears that clinically, in the majority of patients administered 
artemisinins,  the  presence  of  malaria  and  dehydration  rather 
than the drug exert the most important effects on hematologic 
parameters. 
 
Testing for G6PD deficiency 
 
It is fortunate that there are today effective antimalarials that can be 
used safely for the treatment of P falciparum infection in G6PD- 
deficient  children.  However,  if  one  had  to  use  a  potentially 
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Treated with dapsone 
  G6PD-deficient males and females (N = 119) 
Heterozygous  females (N = 200) 
G6PD-normal  males and females (N = 1145) 
Control (artemether-lumefantrine) 
All patients (N = 366) 
 
Figure 5. The G6PD genotype was a major determinant of the severity of anemia in children given dapsone. The cumulative frequency of the maximum decrease in 
hemoglobin concentration versus pretreatment levels in G6PD-normal children given dapsone was similar to that of the control group; in G6PD-deficient children it is much 
greater, and in girls heterozygous for G6PD deficiency it is intermediate. 
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Figure 6. Illustrative examples of the hematologic 
impact of dapsone in individual patients with falci- 
parum malaria. These 4 girls were all from the same site 
(Ouagadougou, Burkina Faso). (A) was G6PD normal, 
(B) was homozygous for G6PD deficiency, and (C) and 
(D) were heterozygous for G6PD deficiency. It is seen 
that one of the heterozygotes behaved almost exactly like 
a G6PD-normal child, whereas the other behaved almost 
exactly like a homozygous G6PD-deficient child. 
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hemolytic agent, as is the case for primaquine with respect to 
Plasmodium vivax eradication, then testing for G6PD deficiency 
would be imperative. Although in the past this has been regarded as 
an unrealistic proposition for many malaria-endemic areas, testing 
is now possible with minimal facilities (rapid diagnosis test) at low 
cost and results can be available within an hour.45 A reservation 
raised commonly with respect to G6PD tests is that they would fail 
to detect a fraction of heterozygotes. This is certainly true, but those 
heterozygotes that risk being misclassified as G6PD normal are 
those that have a majority of G6PD-normal erythrocytes, and 
therefore they are unlikely to develop a serious hemolytic attack. 
 
Severe hemolytic anemia in G6PD A- 
 
Since the 1960s, a widespread notion about the risk of AHA in 
G6PD deficiency has been that its severity depends on the specific 
G6PD variant involved.46 This was based largely on the observa- 
tion that when primaquine was administered experimentally to 
G6PD-deficient subjects from Sardinia (who presumably had the 
G6PD Mediterranean mutation),47  it caused a more severe hemo- 
lytic attack than previously reported in African-Americans with 
G6PD A-.30 In addition, the mean value of G6PD activity in 
erythrocytes with G6PD Med is lower than in erythrocytes with 
G6PD A-. A statement in the report of a WHO meeting held in 
1966 led to the term “mild” being used for G6PD A-.46  This 
document also stated that favism, a severe clinical manifestation 
of G6PD deficiency, did not occur in G6PD A- individuals.46 
However, it became clear subsequently that this statement was 
incorrect: subjects with G6PD A- can develop severe favism.48-50 
Despite numerous case reports of severe hemolysis occurring 
after oxidative challenge in patients with G6PD A-, the notion 
that the clinical implications of G6PD A- are generally mild 
has persisted. It is evident from this analysis that patients with 
G6PD A- are at risk of a serious hemolytic attack whenever the 
trigger is powerful enough. It remains of course possible that 
with the same dose of dapsone that was used in these children, 
hemolytic attacks might be even more severe with other G6PD 
variants. In the meantime, we submit that the term “mild” for the 
G6PD A- type of G6PD deficiency can be misleading and 
should best be abandoned. 
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